Cnj-016 Market Report 2026

Cnj-016 Market Overview

• The Cnj-016 market growth in the historic period has been driven by smallpox vaccination adverse event management, biodefense preparedness initiatives • Market expansion is supported by renewed biodefense investments, expansion of national stockpiles • Growth Driver: Rising Prevalence Of Immunodeficiency Diseases Fuels Growth In The CNJ-016 Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Cnj-016 Market?

CNJ-016 refers to a vaccinia immune globulin (VIG) product, a biological treatment used to manage severe complications from smallpox vaccination, such as eczema vaccinatum. It is derived from human plasma and is rich in antibodies against the vaccinia virus. This treatment is primarily used in patients who experience life-threatening reactions to the vaccinia virus, including those with eczema or compromised immune systems. The main clinical indications in the cnj-016 market are eczema vaccinatum, progressive vaccinia, and severe generalized vaccinia. Eczema vaccinatum refers to a rare but severe complication that can occur in individuals with eczema (atopic dermatitis) after they are exposed to the vaccinia virus, often through smallpox vaccination. The different distribution channels include direct sales, pharmaceutical wholesalers, online pharmacies, and retail pharmacies, and several end users, including hospitals, clinics, and homecare.

What Is The Cnj-016 Market Growth Forecast?

The growth in the forecast period can be attributed to renewed biodefense investments, expansion of national stockpiles, improved plasma collection networks, rising immunocompromised populations, global health security strategies. Major trends in the forecast period include increased preparedness for smallpox vaccine complications, strategic stockpiling of vaccinia immune globulin, focus on immunocompromised patient safety, government led biodefense programs, expansion of plasma derived antibody therapies.

Global Cnj-016 Market Segmentation

1) By Clinical Indication: Eczema Vaccinatum, Progressive Vaccinia, Severe Generalized Vaccinia 2) By Distribution Channel: Direct Sales, Pharmaceutical Wholesalers, Online Pharmacies, Retail Pharmacies 3) By End User: Hospitals, Clinics, Homecare

What Are The Drivers Of The Cnj-016 Market?

The increasing prevalence of immunodeficiency diseases is expected to propel the growth of the cnj-016 market going forward. Immunodeficiency diseases are disorders in which the immune system's ability to fight infections and diseases is compromised or entirely absent. The increasing prevalence of immunodeficiency is due to factors such as genetic, environmental, or related specific medical conditions and treatments. CNJ-016, a vaccinia immune globulin, helps patients with immunodeficiency diseases by providing passive immunity, offering protection against complications like eczema vaccinatum, progressive vaccinia, and other vaccinia virus-related adverse events, particularly in patients with weakened immune systems. For instance, in November 2025, according to Immunodeficiency UK, a UK-based charity, more than 5,000 people in the United Kingdom were documented as having one of over 450 identified primary immunodeficiency conditions in 2025, most of which are genetic disorders present from birth. Thus, the increasing prevalence of immunodeficiency diseases is driving the growth of the cnj-016 industry. Rise in smallpox vaccination is expected to propel the growth of the cnj-016 market going forward. Smallpox vaccination refers to the administration of a vaccine to provide immunity against smallpox, a highly contagious and potentially deadly viral disease caused by the variola virus. Smallpox vaccination is on the rise due to increasing global health concerns over the potential reemergence of infectious diseases. Cnj-016 helps in smallpox vaccination by providing passive immunity to individuals with weakened immune systems or those at risk of complications from the vaccinia virus, which can be used in smallpox vaccination. For instance, in May 2023, according to the Centers for Disease Control and Prevention, a US-based government agency, 1.2 million doses of JYNNEOS had been administered, achieving about 37% first-dose coverage and 23% second-dose coverage among the estimated at-risk population. Thus, the rise in smallpox vaccination is driving the growth of the cnj-016 industry. The increasing focus on personalized medicine is expected to propel the growth of the cnj-016 market going forward. Personalized medicine is a healthcare strategy that customizes treatments and therapies according to a person's genetic makeup, environment, and lifestyle. Personalized medicine is rising due to advancements in genomic technologies, increasing access to big data analytics, and the growing availability of targeted therapies tailored to individual genetic profiles. CNJ-016 offers targeted treatment options for individuals with compromised immune systems, helping to reduce the risk of complications from vaccinations or viral infections based on their specific medical needs and immune profiles. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based nonprofit organization, the USFDA approved 16 new personalized treatments for rare disease patients in 2023, a significant increase from 6 personalized treatments in 2022. Therefore, the increasing focus on personalized medicine is driving the growth of the cnj-016 industry.

Key Players In The Global Cnj-016 Market

Major companies operating in the cnj-016 market are Emergent Biosolutions Inc.

Regional Insights

North America was the largest region in the cnj-016 market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Cnj-016 Market?

The cnj-016 market consists of sales of human immune globulin and Vaccinia immune globulin intravenous. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Cnj-016 Market Report 2026?

The cnj-016 market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the cnj-016 industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.